Gilead Allergan Seen Trailing Intercept In Ongoing NASH Battle

September 23, 2016 | Gilead is trailing Intercept in the battle against NASH, Credit Suisse analyst Alethia Young said Thursday, two days after Botox maker Allergan jumped in. Investor's Business Daily